Q3 FY26 Concall · Feb 13, 2026
Shaily Engineering Plastics Q3 FY26 Concall Decoded:
GLP-1 Pens Go Brrr, But High-Speed Lines Go ‘Qualification Dance’
A plastic pen maker that grew revenue 27%, EBITDA 43%, opened a ₹350-crore Abu Dhabi factory, and somehow convinced 100-year-old investors that waiting 18 months for capacity is actually a feature, not a bug.
Q3 Revenue₹251 Cr
Revenue Growth+27% YoY
EBITDA Growth+43% YoY
EBITDA Margin26.5%
PAT Growth+48% YoY
01 — Opening Hook
The Plastic Surgeon of Pharma Devices
Imagine a company that makes plastic pens for diabetics and cardiac patients. Imagine they just told the market: “We’re building a ₹350-crore factory in Abu Dhabi, hiring a COO from Taiwan who managed 7 manufacturing plants, and we’ve already sold 65-75% of the capacity to customers we can’t name.” Then imagine investors ask: “But when will this thing actually run?” And management says: “Dude, ask us in 18 months.” Welcome to Shaily—where GLP-1 mania meets manufacturing reality.
Q3 FY26 delivered the kind of numbers that make PowerPoint slides glow: ₹251 crores revenue (+27% YoY), ₹66 crores EBITDA (+43% YoY), 26.5% margins. Healthcare segment now 42% of the pie. But here’s the joke: the company’s main assembly line is still in “qualification”—which is corporate-speak for “we built a Ferrari but it’s still learning to drive.” Read on to decode what happens when a plastic molds company becomes a GLP-1 monopoly play.
Heads Up: Management committed ₹300-350 crores capex for Abu Dhabi without issuing shares. Debt stays low, but this is a calculated bet that Ozempic demand never cools off. It won’t. But competition will. Margins always do.
02 — At a Glance
The Quarterly Plastic Fantastic
Q3 Revenue
₹251 Cr
+27% YoY. Healthcare alone grew 139%. Everything else is rounding error.
EBITDA Growth
+43% YoY
₹66 Cr. Margin 26.5%. The GLP-1 business prints money. Consumer segment bleeds it.
PAT Growth
+48% YoY
₹37 Cr net profit. Shareholders go brrrr. Capex approval goes brrrr harder.
9M FY26 EBITDA
+76% YoY
₹218 Cr. 29% margin. The margin expansion story is real—not a mirage.
Cash PAT 9M
₹166 Cr
+73% YoY. Working capital wasn’t screaming. Yet.
The Reality Check: Revenue up 27%, profit up 48%. Margins expanding. But this is a one-product-line story with gestation delays baked in. Scale now, regret pricing later. It’s the Semaglutide tango.
03 — Management’s Key Commentary
What They Said (And What It Actually Means)
Amit Sanghvi (MD): “The first high-speed line is going through operational qualification, should be completed next week. The second line will arrive end of April, beginning of May, and will be commercialized by end of July.”
😅 Translation: We ordered these machines 15 months ago. They’re finally here. Now we get to find out if they actually work. Spoiler alert: they don’t. Not yet. Qualification is slow.
Amit Sanghvi: “We’ve established a new scalable facility in Abu Dhabi. Planned investment AED130-150 million (₹300-350 crores). 75 million pen injectors per year. Operational by Q4 FY’28.”
🤑 Translation: We’re going big. 50-60% of capacity already backed by contracts we can’t discuss. This is a ₹350-crore bet that GLP-1 demand stays insane forever. Or at least 10 years.
Amit Sanghvi: “We’ve already started supplying GLP-1 injectors for commercial launches in Canada, Brazil, India, Middle East, Turkey. Customers are breathing down our necks for supply.”
💨 Translation: Demand is real. Our capacity constraints are a feature. We’re leaving money on the table every week because the line isn’t running. This is suffering from success.
Amit Sanghvi: “In Canada, among first 6-7-8 filers, we have upwards of 65-75% market share.”
🍁 Translation: Basically everyone in Canada using GLP-1s is using our pens. We own the supply chain right now. Until we don’t.
Amit Sanghvi: “The consumer electronics business is going to come from customers setting up final assembly in India. We’ll participate in high complexity, high precision, small parts.”
🎯 Translation: China+One is real. We want a slice. China plastic guys make $300M-600M revenue annually in this space. We’re hungry.
Amit Sanghvi: “We’re looking at 30 million pens guidance for FY26. With new capacity coming, this should scale substantially.”
📊 Translation: 30M is locked down. 50M+ is the dream. But we need the lines to actually work first.
04 — Numbers Decoded
The Financial Scorecard
